Drugs / teverelix TFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04693507 | Mar 2021 → Dec 2022 | prostatic adenoma | Antev Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | teverelix TFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04693507 ↗ |
| Known as | Teverelix Trifluoroacetate | “An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist,...” NCT04693507 ↗ |
| Action | Inhibit | “Teverelix Trifluoroacetate, a GnRH Antagonist” NCT04693507 ↗ |
| Route | Intramuscular | “one subcutaneous (SC) injection in the abdomen and one intramuscular (IM) injection in the buttock” NCT04693507 ↗ |
| Route | Subcutaneous | “one subcutaneous (SC) injection in the abdomen and one intramuscular (IM) injection in the buttock” NCT04693507 ↗ |